Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
(TheNewswire)
Kelowna, British Columbia –November 12, 2025 – TheNewswire - Lexaria Bioscience Corp.(Nasdaq: LEXX, LEXXW) (the "Company" or"Lexaria"), a global innovator in drug delivery platforms,provides this update on the Material TransferAgreement (“MTA”) originally entered into on September 4, 2024 with a pharmaceutical
company (“PharmaCO”) to evaluateLexaria’s DehydraTECHTM technology in a pre-clinicalsetting.
The original agreement has been extended through April30, 2026, to accommodate time needed for PharmaCO’s receipt andreview of the full dataset from Lexaria’s Australian study, at whichtime further information will be provided. This allows the two partiesto continue their relationship under the MTA, keep the temporaryexclusive license active and in force, and contemplate additionalstrategic planning discussions with PharmaCO’s human clinicaldevelopment team.
Earlier in 2025, initial pre-clinical studies coveredby the MTA, which examined pharmacokinetics in animals, had beencompleted. At that time, Lexaria had been informed by PharmaCO thatthey wished to review the pending safety (adverse events),pharmacokinetic and efficacy data from Lexaria’s independent,Australian human clinical study GLP-1-H24-4, which is currently
at the stage of full sample and data analyses as previously
announced. Lexaria expects to release the final results of theAustralian study when available, which is currently projected to bebefore the end of the fourth quarter of calendar 2025.
About Lexaria Bioscience Corp. &DehydraTECH
DehydraTECH™ is Lexaria’s patented drug deliveryformulation and processing platform technology which improves the waya wide variety of drugs enter the bloodstream, always through oraldelivery. DehydraTECH has repeatedly evidenced the ability toincrease bio-absorption, reduce side-effects, and deliver some drugsmore effectively across the blood brain barrier. Lexaria operates alicensed in-house research laboratory and holds a robust intellectualproperty portfolio with 54 patents granted and additional patentspending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKINGSTATEMENTS
This press release includes forward-looking statements.Statements as such term is defined under applicable securities laws.These statements may be identified by words such as"anticipate," "if," "believe,""plan," "estimate," "expect,""intend," "may," "could,""should," "will," and other similar expressions.Such forward-looking statements in this press release include, but arenot limited to, statements by the Companyrelating to use of proceeds from the offering and relating to the Company’s ability to carry out researchinitiatives, receive regulatory approvals or grants or experiencepositive effects or results from any research or study. Suchforward-looking statements are estimates reflecting the Company'sbest judgment based upon current information and involve a number ofrisks and uncertainties, and there can be no assurance that theCompany will actually achieve the plans, intentions, or expectationsdisclosed in these forward-looking statements. As such, you shouldnot place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially fromthose estimated by the Company include, but are not limited to,market and other conditions, government regulation and regulatory approvals, managing andmaintaining growth, the effect of adverse publicity, litigation,competition, scientific discovery, the patent application and approvalprocess, potential adverse effects arising from the testing or use ofproducts utilizing the DehydraTECH technology, the Company’s abilityto maintain existing collaborations and realize the benefits thereof,delays or cancellations of planned R&D that could occur related topandemics or for other reasons, and other factors which may beidentified from time to time in the Company's publicannouncements and periodic filings with the US Securities and ExchangeCommission on EDGAR. The Company provides links to third-partywebsites only as a courtesy to readers and disclaims anyresponsibility for the thoroughness, accuracy or timeliness ofinformation at third-party websites. There is no assurance that any ofLexaria’s postulated uses, benefits, or advantages for the patentedand patent-pending technology will in fact be realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-lookingstatements or links to third-party websites contained herein, whetheras a result of any new information, future events, changedcircumstances or otherwise, except as otherwise required bylaw.
INVESTOR CONTACT:
George Jurcic - Head of InvestorRelations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
Copyright (c) 2025 TheNewswire - All rights reserved.